VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits

22 Sep 2017 - Yahoo News
ISNES, Belgium, Sept. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its strategy for a new range of Clinical Research Use Only (RUO) kits based on its proprietary Nucleosomics™ technology and the receipt of an order of RUO kits from a large multinational ...
usx:vnrx

---

VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding

21 Sep 2017 - Yahoo News
ISNES, Belgium, Sept. 21, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded a loan and a non-repayable grant totaling $1.5 million from SOFINEX and the Walloon Region, Belgium. Dr. Gaetan Michel, Chief Executive Officer of Volition's ...
usx:vnrx

---

VolitionRx Announces its European Colorectal Cancer Strategy

19 Sep 2017 - Yahoo News
ISNES, Belgium, Sept. 19, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its colorectal cancer (CRC) strategy for Europe. As part of its strategy, Volition plans to select a frontline panel to be validated in two large trials (4,300 and 10,000 sample), followed ...
usx:vnrx

---

VolitionRx to Attend Two Major Conferences in Asia

15 Sep 2017 - Yahoo News
Volition's Vice President of Asia, Dr. Jasmine Kway, commented, "Asia is a very important market for Volition and we have made significant progress in the region since January of this year. There is a growing aging population in many countries in Asia, with more than 40% of worldwide colorectal cancers ...
usx:vnrx

---

Volition Granted Four Additional Patents

14 Sep 2017 - Yahoo News
ISNES, Belgium, Sept. 14, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been granted four additional patents relating to its proprietary Nu.QTM platform. The newly-issued patents further strengthen Volition's intellectual property portfolio worldwide. ...
usx:vnrx

---

VolitionRx Limited to Attend Multiple Conferences in September

6 Sep 2017 - Yahoo News
ISNES, Belgium , Sept. 6, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced that its Chief Executive Officer, Cameron Reynolds , its Executive Vice President, Scott Powell ...
usx:vnrx

---

VNRX: Pathway Design Study Progressing. Expect European Launch in 2018

30 Aug 2017 - Yahoo News
VolitionRx (VNRX) reported Q2 results and provided an operational update. Relative to the financials, the $3.5M in operating expenses were inline with our $3.6M estimate. We continue to model only incremental growth in operating expenses through the remainder of 2017, despite expectations of additional ...
usx:vnrx

---

Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers

22 Aug 2017 - Yahoo News
ISNES, Belgium, Aug. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) today announced a three-year agreement to work with the renowned expert Professor Stefan Holdenrieder at the Institute of Laboratory Medicine of the German Heart Center at the Technical University of Munich, Germany. ...
usx:vnrx

---

VolitionRx targeting several milestones in second half of 2017 - Proactive Investors USA & Canada

10 Aug 2017 - Proactive Investors USA & Canada

usx:vnrx

---

VolitionRX reports 2Q loss

10 Aug 2017 - Yahoo News
On a per-share basis, the Singapore-based company said it had a loss of 13 cents. The company's shares closed at $2.86. A year ago, they were trading at $3.31. _____ This story was generated by Automated ...
usx:vnrx

---